Changes

Jump to navigation Jump to search
4,382 bytes added ,  16:18, 28 November 2023
no edit summary
Line 1: Line 1:  +
<span style="color:#0070C0">(''General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see'' </span><u>''[[Author_Instructions]]''</u><span style="color:#0070C0"> ''and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])''</span>
 +
 
==Primary Author(s)*==
 
==Primary Author(s)*==
   −
Put your text here
+
Put your text here<span style="color:#0070C0"> (''Name and affiliation; example:'' Jane Smith, PhD, Institute of Genomics) </span>
    
__TOC__
 
__TOC__
   −
==Cancer Category/Type==
+
==Cancer Category / Type==
    
Put your text here
 
Put your text here
Line 11: Line 13:  
==Cancer Sub-Classification / Subtype==
 
==Cancer Sub-Classification / Subtype==
   −
Put your text here
+
Put your text here  
    
==Definition / Description of Disease==
 
==Definition / Description of Disease==
   −
Put your text here
+
Put your text here <span style="color:#0070C0">(''Instructions: Brief description of approximately one paragraph - include disease context relative to other WHO classification categories referring to the specific WHO book pages, diagnostic criteria if applicable, and differential diagnosis if applicable'') </span>
    
==Synonyms / Terminology==
 
==Synonyms / Terminology==
   −
Put your text here
+
Put your text here <span style="color:#0070C0">(''Instructions: Include currently used terms and major historical ones, adding “(historical)” after the latter.'') </span>
    
==Epidemiology / Prevalence==
 
==Epidemiology / Prevalence==
Line 27: Line 29:  
==Clinical Features==
 
==Clinical Features==
   −
Put your text here and fill in the table
+
Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table'') </span>
 
{| class="wikitable"
 
{| class="wikitable"
 
|'''Signs and Symptoms'''
 
|'''Signs and Symptoms'''
Line 46: Line 48:  
==Sites of Involvement==
 
==Sites of Involvement==
   −
Put your text here
+
Put your text here <span style="color:#0070C0">(''Instruction: Indicate physical sites; Example: nodal, extranodal, bone marrow'') </span>
    
==Morphologic Features==
 
==Morphologic Features==
Line 54: Line 56:  
==Immunophenotype==
 
==Immunophenotype==
   −
Put your text here and fill in the table
+
Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table'') </span>
    
{| class="wikitable sortable"
 
{| class="wikitable sortable"
Line 91: Line 93:  
|}
 
|}
 
 
==Individual Region Genomic Gain/Loss/LOH==
+
==Individual Region Genomic Gain / Loss / LOH==
   −
Put your text here and fill in the table
+
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>
    
{| class="wikitable sortable"
 
{| class="wikitable sortable"
Line 139: Line 141:  
==Characteristic Chromosomal Patterns==
 
==Characteristic Chromosomal Patterns==
   −
Put your text here
+
Put your text here <span style="color:#0070C0">(''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis'')</span>
    
{| class="wikitable sortable"
 
{| class="wikitable sortable"
Line 159: Line 161:  
See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).
 
See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).
 
|}
 
|}
==Gene Mutations (SNV/INDEL)==
+
==Gene Mutations (SNV / INDEL)==
   −
Put your text here and fill in the table
+
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>
    
{| class="wikitable sortable"
 
{| class="wikitable sortable"
Line 198: Line 200:  
==Genes and Main Pathways Involved==
 
==Genes and Main Pathways Involved==
   −
Put your text here and fill in the table
+
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the table.'')</span>
 
{| class="wikitable sortable"
 
{| class="wikitable sortable"
 
|-
 
|-
Line 221: Line 223:  
==Familial Forms==
 
==Familial Forms==
   −
Put your text here
+
Put your text here <span style="color:#0070C0">(''Instructions: Include associated hereditary conditions/syndromes that cause this entity or are caused by this entity.'') </span>
    
==Additional Information==
 
==Additional Information==
Line 229: Line 231:  
==Links==
 
==Links==
   −
Put your text placeholder here (use "Link" icon at top of page)
+
Put your text placeholder here (or anywhere appropriate on the page) and use the "Link" icon at the top of the page <span style="color:#0070C0">(''Instructions: Once you have a text placeholder entered to which you want to add a link, highlight that text, select the "Link" icon at the top of the page, and search the name of the internal page to which you want to link this text, or enter an external internet address including the "<nowiki>http://www</nowiki>." portion.'')</span>
    
==References==
 
==References==
<references />
+
(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted.''</span> <span style="color:#0070C0">''If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">) </span> <references />
(use "Cite" icon at top of page)
      
'''EXAMPLE Book'''
 
'''EXAMPLE Book'''

Navigation menu